Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 17, 2022
Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the...
-
Sep 6, 2022
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation MARLBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Boston...
-
Aug 16, 2022
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events. On Wednesday, September 7, 2022, Mike Mahoney, chairman and chief executive officer, and Lauren Tengler,...
-
Aug 15, 2022
Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass., Aug. 15, 2022 /PRNewswire/ -- Boston Scientific...
-
Jul 27, 2022
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and...
-
Jun 29, 2022
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27,...
-
Jun 15, 2022
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64...
-
May 2, 2022
Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12. Dan Brennan, executive vice president and chief financial officer, and
-
Apr 27, 2022
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD™ Fibered Detachable Coil,...
-
Apr 27, 2022
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis...
-
Apr 11, 2022STIMVIEW™ XT, developed in collaboration with Brainlab AG, provides clinicians with real-time, 3D visualization and stimulation of brain anatomy
Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for its latest image guided...
-
Apr 1, 2022
Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27,...
-
Mar 16, 2022
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the "Tender Offer") for $2,852,561,000 in...
-
Mar 16, 2022
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate...
-
Mar 8, 2022
Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of...
-
Mar 4, 2022
Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of...
-
Mar 2, 2022
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount (the...
-
Feb 28, 2022
Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device....
-
Feb 15, 2022
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as...
-
Feb 14, 2022
Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022. Dan Brennan, executive vice president and chief...
-
Feb 2, 2022
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational1 basis...
-
Jan 7, 2022
Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on...
-
Jan 4, 2022
Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. Mike Mahoney, chairman and chief executive officer,...
-
Dec 2, 2021Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...
-
Nov 8, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2021, Dan Brennan, executive vice president and chief financial officer, and Lauren...
-
Oct 27, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and...
-
Oct 20, 2021Terms Include Patent License for Micro-Tech’s Continued Sales of Hemostasis Clips
October 20, 2021 – Boston Scientific Corporation announces that it reached a settlement with Micro-Tech Endoscopy resolving claims of patent infringement by Boston Scientific against Micro-Tech...
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 6, 2021Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to...
-
Oct 5, 2021Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism
Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
-
Oct 4, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October...
-
Sep 21, 2021Company to add mechanical thrombectomy platform to peripheral interventions portfolio
Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints,...
-
Sep 9, 2021Company leaders will present long-range strategy and financial goals in addition to market overviews and pipeline updates
Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30...
-
Sep 1, 2021
Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based...
-
Aug 10, 2021
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside...
-
Aug 4, 2021Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism
Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and...
-
Aug 2, 2021New Technology Add-on Payment can increase patient access to ERCP procedures with reduced infection risks
Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the...
-
Jul 27, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis...
-
Jul 21, 2021PINNACLE FLX study meets 24-month endpoint, reinforces positive 12-month outcomes with next-generation device for patients with non-valvular atrial fibrillation
Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...
-
Jun 29, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021...
-
Jun 24, 2021
Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately. Wichmann recently served as chief executive officer of...
-
Jun 24, 2021Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...
-
May 25, 2021
Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the...
-
May 24, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021. Mike Mahoney, chairman and chief executive officer,...
-
May 18, 2021
Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and...
-
May 3, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On May 11, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa,...
-
Apr 28, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an...
-
Mar 26, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28,...